Companies
Sichuan University National Engineering Research Center for Biomaterials
published a 2026 regulatory-science paper proposing a progressive strategy for pre-market immunological evaluation of recombinant collagen medical devices, co-authored with device manufacturers including Gempharmatech, Jiangsu Trautec Medical Technology and Shanghai LabEx Biotech.
- Country
- China
regulatory-science
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| fibers-textiles | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Affiliation | National Engineering Research Center for Biomaterials, Sichuan University | biomater.scu.edu.cn · international.scu.edu.cn · journal.hep.com.cn |
| Research focus | biomaterials for tissue regeneration, functional reconstruction, medical implants, and immunological evaluation of protein-based medical devices | biomater.scu.edu.cn · international.scu.edu.cn · journal.hep.com.cn |
| Facility | Sichuan Testing Centre for Biomaterials and Medical Devices | biomater.scu.edu.cn |
| Grant | National Key R&D Program of China (2024YFC2420800), Beijing Natural Science Foundation (L244001), Jiangsu High-level Innovative and Entrepreneurial Talents (JSSCRC2024490), China NMPA Research on performance and safety evaluation of innovative biomaterial medical devices (RS2024X004) | journal.hep.com.cn |
| Publications | Over 2,000 papers in core journals and over 500 papers in peer-reviewed international journals | biomater.scu.edu.cn · international.scu.edu.cn |
| Principal staff | Zhang Xingdong, Yujiang Fan, Haihang Li, Tun Yuan, Xiaoyumei Xiao | biomater.scu.edu.cn |
| Headcount | Over 300 total personnel as of 2025; 74 staff in primary teaching/research team (1970-01-01) | biomater.scu.edu.cn |
Independent sources: biomater.scu.edu.cn · international.scu.edu.cn · journal.hep.com.cn
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant collagen & gelatin | fibers-textiles | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.